Intech Investment Management LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

Intech Investment Management LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 8,108 shares of the company’s stock, valued at approximately $368,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Janux Therapeutics during the first quarter worth approximately $739,000. DNB Asset Management AS acquired a new position in Janux Therapeutics in the second quarter worth approximately $221,000. SG Americas Securities LLC bought a new position in shares of Janux Therapeutics in the second quarter valued at $1,452,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Janux Therapeutics by 136.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock valued at $4,818,000 after acquiring an additional 66,340 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on JANX shares. Wedbush restated an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday. Scotiabank reduced their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Stifel Nicolaus lifted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Leerink Partners boosted their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $77.90.

Janux Therapeutics Trading Up 49.0 %

Shares of NASDAQ:JANX opened at $59.86 on Wednesday. Janux Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $71.25. The business has a fifty day simple moving average of $49.60 and a 200 day simple moving average of $45.72.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue was down 82.6% on a year-over-year basis. Analysts expect that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was bought at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the acquisition, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. The trade was a 14.78 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the transaction, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. The trade was a 5.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 460,610 shares of company stock worth $21,583,666. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.